Tougher pre-market plans worry Australian medtech industry
This article was originally published in SRA
Executive Summary
Proposals by Australia's Therapeutic Goods Administration to increase its pre-market scrutiny of medical devices and improve transparency around its decision-making process have drawn concern from medtech, in vitro diagnostic and biotech companies.